Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by University of Oklahoma.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Mark L. Wolraich, M.D.
Eli Lilly and Company
Information provided by (Responsible Party):
University of Oklahoma
ClinicalTrials.gov Identifier:
NCT00417794
First received: January 2, 2007
Last updated: February 6, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.


Condition Intervention Phase
Fetal Alcohol Syndrome
Attention Deficit Disorder With Hyperactivity (ADHD)
Attention Deficit Disorder (ADD)
Drug: Strattera
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects

Resource links provided by NLM:


Further study details as provided by University of Oklahoma:

Primary Outcome Measures:
  • ADHD Rating Scale - IV [ Time Frame: length of protocol ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine if atomoxetine is safe and well tolerated by children with FAS. [ Time Frame: length of protocol ] [ Designated as safety issue: Yes ]
  • Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo. [ Time Frame: length of protocol ] [ Designated as safety issue: No ]
  • Determine if atomoxetine improves behaviors in the mornings and evenings. [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]
  • Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine. [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]
  • Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine. [ Time Frame: Length of protocol ] [ Designated as safety issue: Yes ]
  • Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI) [ Time Frame: Length of protocol ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: June 2006
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Atomoxetine HCL (Strattera)
Drug: Strattera
escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
Other Name: atomoxetine HCL
Placebo Comparator: 2 Drug: Placebo
0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.

Detailed Description:

Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (FAS) and ADHD. Atomoxetine Hydrochloride is a non-stimulant medication used to treat ADHD. This study will determine if atomoxetine HCL significantly reduces symptoms of ADD/ADHD in children with fetal alcohol exposure.

  Eligibility

Ages Eligible for Study:   4 Years to 11 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must be between the ages of 4 and 11 years at the time of entry into the study.
  • Patients must meet diagnostic criteria for FASD
  • Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of > or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age.
  • Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2.
  • History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study.
  • Patients must be able to swallow capsules.
  • Patients must be of a sufficient developmental level (~3 yrs) to participate in the study.
  • Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection.
  • Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD.

Exclusion Criteria:

  • Have received an in investigational medication in the past 30 days.
  • Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated.
  • Have significant current medical conditions that could be exacerbated or compromised by atomoxetine.
  • Have used MAOIs within one month prior to visit 2.
  • Patients with hypertension.
  • Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder.
  • Patients taking anticonvulsants for seizure control.
  • Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2.
  • Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring.
  • Pubertal girls.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417794

Contacts
Contact: Lora D Tusing, BS, RN 405-271-5700 ext 45167 lora-tusing@ouhsc.edu
Contact: Brenda Schlinke, R.N. 405-271-5700 ext 45167 brenda-schlinke@ouhsc.edu

Locations
United States, Oklahoma
OU Child Study Center Recruiting
Oklahoma City, Oklahoma, United States, 73117
Contact: Lora D Tusing, BS, RN    405-271-5700 ext 45167    lora-tusing@ouhsc.edu   
Contact: Brenda Schlinke, RN    405-271-5700 ext 45167    brenda-schlinke@ouhsc.edu   
Principal Investigator: Thomas M Lock, M.D.         
Sub-Investigator: Mark L Wolraich, M.D.         
Sub-Investigator: Laura J McGuinn, M.D.         
Sponsors and Collaborators
University of Oklahoma
Mark L. Wolraich, M.D.
Eli Lilly and Company
Investigators
Principal Investigator: Thomas M. Lock, M.D. University of Oklahoma
  More Information

No publications provided

Responsible Party: University of Oklahoma
ClinicalTrials.gov Identifier: NCT00417794     History of Changes
Other Study ID Numbers: B4Z-MC-X017
Study First Received: January 2, 2007
Last Updated: February 6, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Oklahoma:
attention deficit hyperactivity disorder
ADHD
fetal alcohol syndrome
FAS
FASD
atomoxetine hcl

Additional relevant MeSH terms:
Fetal Alcohol Spectrum Disorders
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Fetal Diseases
Pregnancy Complications
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Atomoxetine
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014